Tekmira Pharmaceuticals Corporation completed an offering of 2,125,000 shares of common stock at a price of US$28.50 per share for gross proceeds of approximately US$60.5 million.
The offering was completed under the Canada/US multijurisdictional disclosure system. The underwriter was also granted a 30-day option to purchase up to an additional 318,750 shares to cover any over-allotments which would result in additional gross proceeds.
Leerink Partners LLC acted as the sole manager for the offering.
Tekmira was represented by Farris, Vaughan, Wills & Murphy LLP with a team led by Hector MacKay-Dunn and included Peter Roth and James Campbell (corporate/securities) and Ron Dueck (tax). Daniel Miller of Dorsey & Whitney LLP acted as Tekmira's US counsel with a team including Clint Foss and Jenn Hu (corporate/securities) and John Hollinrake (tax).
Leerink Partners LLC was represented by Blake, Cassels & Graydon LLP with a team led by Joseph Garcia that included Amanda Willett and Sandra Raath (securities) and Soraya Jamal (tax); and by Goodwin Procter LLP with a team led by Thomas Levato.
The offering was completed under the Canada/US multijurisdictional disclosure system. The underwriter was also granted a 30-day option to purchase up to an additional 318,750 shares to cover any over-allotments which would result in additional gross proceeds.
Leerink Partners LLC acted as the sole manager for the offering.
Tekmira was represented by Farris, Vaughan, Wills & Murphy LLP with a team led by Hector MacKay-Dunn and included Peter Roth and James Campbell (corporate/securities) and Ron Dueck (tax). Daniel Miller of Dorsey & Whitney LLP acted as Tekmira's US counsel with a team including Clint Foss and Jenn Hu (corporate/securities) and John Hollinrake (tax).
Leerink Partners LLC was represented by Blake, Cassels & Graydon LLP with a team led by Joseph Garcia that included Amanda Willett and Sandra Raath (securities) and Soraya Jamal (tax); and by Goodwin Procter LLP with a team led by Thomas Levato.
